Itranols

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Itranols

Property Description
Active ingredient Itraconazole
Form Oral Capsule, Oral Solution
Pharmacological class Systemic Antifungal
Common use Treating fungal and yeast infections
Origin Synthetic (Triazole derivative)

Classification and Core Composition of Itranols

Itranols is a pharmaceutical preparation containing the single active ingredient, itraconazole, a synthetic triazole antifungal agent. This places the medicine within the broader therapeutic group of systemic antifungals and antimycotics, meaning it is specifically engineered to combat infections caused by various fungal organisms throughout the body. The drug is classified as a triazole due to its characteristic molecular structure, which provides a broad-spectrum capability against a diverse range of pathogenic fungi. This classification affirms that Itraconazole is recognized in clinical practice for its effectiveness against a wide variety of fungal strains that cause systemic diseases.


Available Forms and Systemic Purpose

Itranols is available for oral administration in two main pharmaceutical preparations: the oral capsule and the oral solution (liquid). Both forms are designed to ensure the itraconazole reaches the systemic circulation, allowing it to effectively target infections deep within body tissues. This medicine's primary general purpose is to manage and eliminate fungal diseases, including superficial conditions and widespread systemic mycoses. The availability of the specialized oral solution distinguishes Itranols, as this formulation is often preferred for immunocompromised patients to ensure more reliable systemic absorption.


How Itraconazole Works Against Fungi (High-Level)

The fundamental action of Itraconazole is to disrupt the protective structure of the fungal cell, thereby inhibiting the infection's ability to grow and spread. This mechanism is achieved by acting as a targeted inhibitor that specifically blocks the production of ergosterol, a crucial structural lipid in the fungal cell membrane. By preventing this essential ergosterol synthesis, the medication compromises the structural integrity of the fungi, which ultimately controls or eliminates the pathogenic organism.

Regulatory References

  1. Itraconazole - StatPearls - NCBI Bookshelf

What side effects are possible with Itranols?

Possible Side Effects and Safety Information

The safety profile for Itranols (itraconazole) is defined by officially documented adverse reactions and strict regulatory warnings, as detailed in governmental prescribing information.


Serious Safety Warnings

Itranols is associated with reports of Congestive Heart Failure (CHF) and a negative inotropic effect (decreased heart contractility), leading to a high-level regulatory warning that contraindicates its use for certain non-life-threatening conditions in patients with a history of CHF. Serious hepatotoxicity, including fatal acute liver failure, has also been documented, sometimes occurring within the first month of treatment. Life-threatening cardiac dysrhythmias may occur, primarily when Itranols is co-administered with certain other medications.


Classification of Common Adverse Reactions

Adverse reactions most frequently reported (often classified as Common) primarily affect the gastrointestinal and nervous systems. These include nausea, vomiting, diarrhea, abdominal pain, headache, and dizziness. Other common effects include rash, pruritus (itching), edema, and changes in physiological measurements such as hypertension and abnormal hepatic function.


Population-Specific Safety Considerations

Caution is advised for specific patient groups. Regulatory documentation advises careful consideration in patients with existing hepatic or renal impairment. For older adults, its use requires caution due to the greater frequency of reduced organ function. Additionally, women of childbearing potential must use effective contraception during and for a period following treatment cessation. The risk of cardiac events has been reported to be associated with the total daily dose, with more reports at the 400 mg level, according to regulatory data.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose of Itranols (itraconazole) is expected to result in an exaggeration of the known adverse effects documented in the medicine's regulatory profile. Due to the potential for severe outcomes, seeking emergency medical help is mandated for a suspected overdose or the onset of specific life-threatening signs.

Officially Documented Severe Outcomes

Regulatory authorities document the potential for severe and life-threatening complications that may be exacerbated by excessive exposure:

  • Cardiovascular Risks: The risk includes life-threatening cardiac dysrhythmias and the development or worsening of Congestive Heart Failure (CHF) symptoms.
  • Hepatic Risks: Overdose carries the risk of fatal acute liver failure. Manifestations such as anorexia, nausea, dark urine, or abdominal pain must prompt immediate action.

Emergency Actions and Management

In the event of a suspected overdose, immediate medical attention is required, and individuals must contact a poison control center or emergency room at once. Furthermore, the medicine must be discontinued immediately if signs of Congestive Heart Failure or Liver Disease appear, as this is a regulator-mandated action.

Management of overdose is limited to symptomatic and supportive treatment, as no specific antidote is documented in the official labeling. Liver function testing is an officially required procedural step if liver-related symptoms are present. Itraconazole is not removed by hemodialysis.

Therapeutic Uses of Itranols

What Itranols Treats: Main Uses and Benefits

Itranols is a systemic antifungal medicine applied across domains where additional symptomatic support is needed for infections caused by certain fungal and yeast organisms. The medication is relevant in contexts involving heightened systemic burden, managing infections like blastomycosis, histoplasmosis, aspergillosis, onychomycosis, and candidiasis.

It is commonly used when supportive symptom management is appropriate to address conditions presenting with systemic or localized discomfort, chronic nail issues, or mucosal pain. The therapeutic support it provides may help ease the overall symptom burden during periods of heightened symptoms.

It is relevant for easing symptoms that interfere with daily functioning, such as the noticeable physiological strain caused by nail thickening and crumbling or the difficulty and pain when swallowing associated with esophageal yeast overgrowth. In high-risk scenarios, it is also applied as prophylaxis to support immunocompromised individuals.


Quick Fact: Relief for Functional Strain

Itranols helps address symptom clusters that may become intense or disruptive, particularly by assisting with general well-being during symptomatic phases when mucosal symptoms interfere with routine activities like eating and drinking.

Regulatory References

  1. NIH MedlinePlus overview of Itraconazole

Eligibility and Restrictions for Use

Eligibility Scope

Population Status Regulatory Classification (Official Labeling)
Use Contraindicated Patients with current or history of congestive heart failure (CHF) or ventricular dysfunction (for non-life-threatening indications).
Patients with known hypersensitivity to itraconazole.
Women who are pregnant (except for life-threatening systemic infections).
Use Not Established Pediatric patients (children and adolescents), as safety and effectiveness are not established in this age group.
Use with Caution/Restricted Patients with hepatic impairment or severe renal impairment must be monitored carefully.
Women of childbearing potential are required to use effective contraception during treatment and for a specified period after discontinuation.
Special Consideration Older adults (geriatric patients), due to the greater frequency of decreased organ function.

Eligibility Classifications

The most severe regulatory status is Contraindicated, which applies to individuals with CHF and those who are pregnant. The Pediatric Population is classified as Use Not Established, limiting standard eligibility. These official classifications strictly define who may use the medicine.

What should I know about interactions with other medicines?

Itranols (Itraconazole) is a potent inhibitor of the human cytochrome P450 3A4 (CYP3A4) enzyme system and can also inhibit P-glycoprotein. These properties form the basis for its major interactions with other medicines.

Contraindicated Combinations (Major Risk)

Co-administration with numerous medicines that are metabolized by the CYP3A4 enzyme is contraindicated due to the risk of significantly increased drug concentrations. The elevated levels of some co-administered drugs can lead to life-threatening cardiac dysrhythmias, including a condition called torsades de pointes. Specific examples of medicines that must not be used with Itranols include certain cholesterol-lowering agents (like lovastatin and simvastatin), select antiarrhythmics, ergot alkaloids (e.g., dihydroergotamine), and certain treatments for erectile dysfunction.

Interactions Requiring Caution or Dose Adjustment

The absorption of Itranols itself can be greatly reduced when co-administered with medicines that decrease stomach acidity, such as H2-receptor antagonists or Proton Pump Inhibitors. This may lead to reduced efficacy of Itranols. Dosage adjustments or careful monitoring may be necessary for other drugs that are CYP3A4 substrates, such as certain immunosuppressants and calcium channel blockers.

Mechanism of Action

How Itranols Works: Mechanism of Action

Itranols functions as an inhibitor targeting a specific fungal enzyme, cytochrome P450 14-alpha-demethylase . This enzyme is essential for the biosynthesis of ergosterol, a key structural lipid that maintains the integrity of the fungal cell membrane, analogous to cholesterol in human cells. By binding to and blocking this enzyme, Itranols stops the conversion of lanosterol into ergosterol.

The resulting lack of functional ergosterol, coupled with the accumulation of toxic precursor sterols, severely compromises the membrane's structural integrity and permeability. This mechanistic cascade leads to the progressive disorganization and functional failure of the fungal cell. The cellular consequence of this targeted pathway disruption is the cessation of growth and replication, culminating in the eventual demise of the fungal cell.

Dosage and Administration Information

How to Use Itranols: Official Administration Guidelines

Itranols is administered via the oral route in two main formulations: the capsule and the oral solution. The proper use of the medicine is critically dependent on following the specific instructions for each form to ensure correct absorption into the systemic circulation.


Form-Specific Intake Conditions

Administration must strictly adhere to whether the capsule or solution form is used, as they are not bioequivalent and should not be substituted for one another.

  • Oral Capsule: Must be taken immediately after a full meal to optimize drug absorption. Capsules must be swallowed whole and not chewed or crushed.
  • Oral Solution: Must be taken on an empty stomach (without food) to maximize its bioavailability. For oral and esophageal fungal issues, the solution is held in the mouth and swished briefly before swallowing.

Dosing and Treatment Duration Patterns

Dosing regimens are distinct for systemic versus localized infections, often involving different frequencies and total durations. Doses exceeding 200 mg per day are typically administered in two divided doses (BID).

Indication Pattern Regimen Summary Duration
Systemic Infections Often begins with a 3-day loading dose of 200 mg three times daily (TID). Long-term, often 6 to 12 months or longer.
Onychomycosis A cyclic pulse dosing schedule is used: 200 mg twice daily for 7 days, followed by a drug-free period. Varies based on number of cycles prescribed.
Oropharyngeal Candidiasis 100 mg to 200 mg once daily (QD). Short-term, typically 1 to 2 weeks.

Population and Procedural Context

Official labeling advises that patients with impaired hepatic function should be monitored carefully. In cases of a missed dose, the next dose should be taken at the regularly scheduled time, and doubling the dose is generally not advised.

Recent Clinical Evidence

Research evidence / Overview of studies for Itranols

Systemic Fungal Infections and Prophylaxis

Itranols was studied in the clinical evaluation of serious, deep-seated fungal diseases like histoplasmosis and blastomycosis, using prospective and Randomized Comparative Trials (RCTs). The outcomes measured included mycological clearance (clearance of the fungus) and the clinical response (resolution or change in physical signs). Studies reported measurements of both mycological clearance and documented clinical resolution in a majority of the observed populations. Research also highlights patterns related to variability in how the medicine is absorbed, which was observed to be associated with different measured outcomes. Evidence is limited for patients with severe or life-threatening systemic disease.

For preventing serious fungal infections (prophylaxis) in high-risk, immunocompromised patients, Itranols was evaluated in Double-blind, Placebo-Controlled RCTs. The primary outcome monitored was the frequency of the occurrence of Invasive Fungal Infections (IFI).

Superficial Infections and Research Durations

For treating onychomycosis (nail fungus), studies primarily examined the combined clinical and mycological outcome—a measurement of clearance and resolution—as well as the rate of recurrence. Research describes that the study groups receiving Itranols reported measurements of the combined outcome rate that differed from groups receiving placebo. Because the nail grows slowly, required follow-up periods are long, sometimes extending up to a year or more to monitor the full effect. This extended observation allows research to provide insight into short-term changes while attempting to capture longer-lasting patterns.

Research Gaps and Limitations

The research landscape for Itranols contains several areas where certainty remains low. A notable limitation is the variability in drug absorption between individuals and across the two formulations (capsule and solution). This means that research highlights group patterns, not personal outcomes. Data for certain groups, particularly children and pregnant populations, remain insufficient, and long-term effects are not fully established for all outcomes. Evidence comparing Itranols to other treatments remains limited.

Key Studies & References Itraconazole Drug Information (Oral Route)

Frequently Asked Questions (FAQ)

Common questions about Itranols (FAQ)


Q: Are there any specific foods or drinks I should avoid while taking Itranols?

Official patient information states that alcohol should be avoided while taking Itranols. Furthermore, depending on the formulation, the medicine is required to be taken with or without food. The capsule form requires consumption with a full meal, but the oral solution is required to be taken on an empty stomach to ensure correct absorption.


Q: Does taking Itranols make you feel tired or drowsy?

Yes, official reports on adverse effects list fatigue (tiredness) and somnolence (drowsiness) as known potential side effects. Like other centrally acting effects such as dizziness, these effects may impact an individual's normal activities.


Q: What happens if Itranols is taken for a long period of time?

Itranols may be prescribed for long periods for serious infections, sometimes lasting 6 to 12 months or longer. While official documents describe the required treatment duration, regulatory documents also caution that long-term effects are not fully established for all possible health outcomes. Careful monitoring by a healthcare provider may be necessary during extended treatment.


Q: Does Itranols need to be taken at a specific time of day?

Official administration instructions emphasize that Itranols is required to be taken in a specific relation to food, but they do not mandate a specific time of day (such as morning or night). The critical timing involves ensuring capsules are taken with a full meal and the solution is taken without food.


Q: Are there any dietary supplements that are known to interact with Itranols?

While specific non-herbal supplements are not explicitly named in warning lists, Itranols inhibits the CYP3A4 enzyme in the body. Since many supplements and over-the-counter products are metabolized by this same enzyme, there is a risk of interaction that may affect the safety or effectiveness of Itranols.


Q: Is there any specific monitoring or testing required while taking Itranols?

Regulatory documents advise that patients with hepatic (liver) function impairment requires careful monitoring. Liver function testing may be necessary before or during treatment to ensure the medicine is handled safely by the body.


Q: What should I know about driving or operating machinery while on Itranols?

Official patient information indicates that Itranols may cause side effects like dizziness or blurred vision. Official guidance indicates caution is advised when performing tasks that require concentration, such as driving or operating machinery, until the individual knows how the medicine affects their function.


Q: How can I tell the difference between a common side effect and a serious one from Itranols?

Regulatory labeling clearly separates Common Adverse Reactions from Serious Safety Warnings. Serious warnings include the risks of Congestive Heart Failure and Hepatotoxicity (serious liver damage), and the signs and symptoms of these conditions should be reported immediately to a healthcare provider.


Q: What is the purpose of the 'Black Box Warning' (if any) associated with Itranols?

The FDA label includes a BOXED WARNING, which is a high-level safety caution, for Itranols. This warning alerts healthcare providers and patients to the risks of Congestive Heart Failure and serious Cardiac Effects. It also highlights the potential for life-threatening Drug Interactions when taken with certain other medicines.


Q: Can Itranols affect sleep patterns?

Yes, official reports on adverse effects list insomnia (difficulty sleeping) as a potential side effect in clinical reporting. This is a recognized effect that may be important to discuss with a healthcare professional.


Q: What is the typical time frame for seeing the full effect of Itranols?

Studies show that it takes approximately 15 days of repeated dosing for Itranols to reach steady-state concentrations (a stable level in the blood). For infections affecting slow-growing tissue like the nails, the full clinical benefit—such as the growth of a healthy nail—may take several months to appear.


Q: How quickly does Itranols typically start working?

After administration, Itranols is relatively quickly absorbed into the body, with peak plasma concentrations typically reached within 2 to 5 hours. However, the full clinical effect on the fungal infection can take longer as the medicine accumulates in the body tissues over days or weeks.


Q: Can Itranols cause changes in weight?

While direct weight change is not typically listed as a common side effect, unexpected weight gain is listed as a potential sign of worsening heart failure. Since this medicine carries a serious warning regarding the heart, unusual weight fluctuations may be a sign of a serious condition and should be reported.


Q: Will Itranols affect the effectiveness of birth control pills?

Official documents require women of childbearing potential to use highly effective contraception during and after treatment with Itranols. Because Itranols interacts with the CYP3A4 enzyme, and some hormonal contraceptives are metabolized by this enzyme, it may interact with the effectiveness of birth control pills.


Q: If I feel better, should I stop taking Itranols?

Official patient information advises that continuation is necessary until told otherwise by a healthcare provider, even if the individual starts to feel well. Fungal infections are often treated over several months to promote cure, and stopping treatment before the full course is completed may increase the risk of the infection returning.


Q: How long does Itranols stay in your system after stopping treatment?

The concentration of the medicine in the blood plasma usually drops to an almost undetectable level within 7 to 14 days after stopping treatment. However, for certain infections like nail fungus, the medicine can persist in the affected tissue, such as the nail bed, for at least six months.


Q: Does Itranols interact with alcohol consumption?

Official patient information explicitly states that alcohol should be avoided while taking Itranols. This warning is in place because alcohol may increase the risk or severity of certain side effects or health issues associated with the medicine.


Q: Are there any known interactions between Itranols and herbal products like St. John's Wort?

Itranols can be affected by substances that influence the P-gp enzyme system in the body. Herbal products such as St. John's Wort are known to increase the activity of this enzyme, which carries a risk of reducing Itranols' effectiveness by lowering its concentration in the bloodstream.


Q: Do men and women experience different side effects from Itranols?

While most common side effects are reported across all populations, official regulatory documents specifically list menstrual disorders as a known adverse effect. This indicates that women may experience certain side effects that are distinct from those experienced by men.


Q: Is the dose of Itranols based on body weight?

Dosing for adults is generally standardized based on the type and severity of the infection. However, for pediatric patients (children), dosing is typically calculated based on body weight, often administered as a set number of milligrams per kilogram of body weight.


Q: Is Itranols known to cause issues with vision?

Yes, vision changes and blurred vision are reported side effects in official safety documents. Patients are advised to contact a healthcare provider immediately if this occurs.


Q: What happens if I stop taking Itranols suddenly?

Official guidance states that stopping treatment without consulting a doctor is not recommended. Fungal infections are often treated over a full course to promote cure, and discontinuing the medicine suddenly may result in the infection not being fully cleared, increasing the likelihood of a relapse.


Q: Does the efficacy of Itranols decrease over time?

Regulatory documents and clinical studies do not indicate that patients develop tolerance, meaning the medicine's core efficacy does not decrease. However, for infections like nail fungus, some research suggests that efficacy may be reduced in older age groups due to natural physiological changes like slower nail growth rates.


Q: Does Itranols have any known effects on fertility?

Preclinical animal studies have been conducted and did not show direct fertility impairment in male or female rats at therapeutic doses. However, due to other risks, women of childbearing potential are required to use highly effective contraception during treatment.

How should Itranols be stored and disposed of?

How to Store and Dispose of Itranols

Itranols (itraconazole) capsules must be stored according to specific environmental and container requirements documented in regulatory labeling to maintain product stability.

Official Storage Requirements

Requirement Specific Condition
Temperature Constraint Store below 25 C
Packaging Keep in the original package
Child Safety Must be kept out of the reach of children

Storage stability is achieved by adhering to the requirement to store the product below 25 C. The requirement to keep the medicine in its original package provides the necessary protection from the surrounding environment.

Disposal

The official regulatory documents state that no special requirements are necessary for the disposal or other handling of unused or expired Itranols product.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Itranols found in:

A-Z Index: